Abstract
pericardium (42%), orbits (25%), and the neuroaxis (51%); 25% have diabetes insipidus (DI). 1, 5 We describe clinical and neuroradiographic features found in an ECD patient cohort.
Methods
Standard protocol approvals, registrations, and patient consents The Mayo Clinic Institutional Review Board (IRB 16-006594) approved this retrospective study. No experiments on live vertebrates or higher invertebrates were performed in this study. Participating patients (or their legally authorized representatives) provided written consent to use medical information. No photographs, videos, or other recognizable information regarding participating patients has been submitted for publication.
We used our institution's medical record diagnostic linkage system to identify patients with pathologically confirmed diagnoses of ECD assessed at Mayo Clinic, Rochester, Minnesota, between January 1, 1990, and July 31, 2016. The search results were cross-referenced with a database of patients with histiocytic disorders maintained within the Mayo Clinic Department of Hematology. Diagnosis was based on histopathology demonstrating CD68+, CD1a-foamy histiocyte infiltration associated with fibrosis according to published guidelines. 2 Diagnosis date was date of first diagnostic biopsy. We extracted data by medical record review. All neuroimaging studies were initially reviewed by a neuroradiologist and subsequently reviewed by 2 neurologists (N.E.P., W.O.T.) using a standard checklist. Disagreements were resolved through consensus.
Kaplan-Meier survival curves of patients with and without radiographic involvement of the CNS were compared using the log-rank test with age adjustment performed using the Cox proportional hazards model. Chi-square statistics evaluated the relationship between BRAF status and radiographic CNS involvement. Radiographic CNS involvement was defined as evidence of dural, brain (including Fazekas score >1), or spinal cord involvement.
Results
We identified 53 patients with pathologically confirmed ECD and reviewed the clinical, radiographic, and pathologic characteristics (table 1) with a focus on neurologic disease.
Clinical
Neurologic symptoms were identified among 47% (25/53) of participants, including imbalance (17), headache (11) , cognitive change (6), dysarthria (6), diplopia (5), dysphagia (4), focal sensory deficit (4), and focal motor deficit (2) . Patients with neurologic symptoms underwent MRI brain. Of the patients with neurologic symptoms (25 patients), the initial diagnostic impressions were histiocytic disorder (5), retroperitoneal fibrosis (2), idiopathic mesenteritis (1), leukemia (1), sarcoidosis (1), polymyalgia rheumatica (1), Paget disease (1), cerebellar ataxia (1), right atrial thrombus (1), large vessel vasculitis (1), pinkeye (1), primary brain tumor (1), periorbital pseudotumors (1), autoimmune pancreatitis (1), DI (1), and unknown (5).
Spinal fluid analyses were available for 8 patients, 5 of which were abnormal. Median white cell count was 1/μL (range 1-29). Median protein was 59 mg/dL (range 31-137). Only 1 patient had oligoclonal bands detected in CSF (3 bands).
Treatment protocols included medication (40 patients) and radiotherapy (19) (table 1). Medications included corticosteroids (26), interferons (12) , cladribine (17) , vemurafenib (10), anakinra (5), methotrexate (8) , infliximab (3), azathioprine (2), ifosfamide (1), etoposide (1), cisplatin (1), cyclophosphamide (1), vinblastine (1), dabrafenib (2), imatinib (1), trametinib (1), etanercept (1), and mycophenolate (1) . No patient had a stem cell transplant. Follow-up data were available on 48 patients (39 treated, 9 untreated). Patients treated with medications had a median increase in disability of 1 (interquartile range [IQR] 0-4) compared to 2 (IQR 0-3.5, p = 0.7, Wilcoxon rank sum test) in patients who did not receive medication as measured by a change in modified Rankin Scale (mRS). Only one patient had an improved mRS score from 1 to 0 at follow-up.
Radiographic
Cranial imaging was obtained for 42 patients with head CT (17), brain MRI (39), orbits MRI (15), and sella MRI (13) . Spine MRI was obtained for 16 patients including cervical (9), thoracic (8), and lumbar (11) Twenty-eight patients had whole body PET-CT with 25/28 being abnormal. Bony abnormalities were seen in 19 patients and extraosseous PET-CT abnormalities were seen in 24 patients. Bone involvement was present without extraosseous disease on PET-CT in only 1 patient, while 6 patients had extraosseous PET-CT abnormalities without bone involvement. Of 32 bone scans obtained, 28 were abnormal. Of the skeletal surveys performed, 28/30 were abnormal.
Dura
Enhancing dural masses (6/41) occurred as solitary (3) and multiple (3) lesions in infratentorial and supratentorial regions ( figure 1A ). Among those with abnormal T2 appearance (4/5), all were hypointense. In a single case, multiple infratentorial dural masses resulted in obstructive hydrocephalus.
CNS parenchyma
Infratentorial T2-hyperintense lesions occurred in the brainstem (9/39) and cerebellum (8/39) (figure 1B). All cases with brainstem involvement affected the pons. Two patients with cerebellar involvement did not have pontine involvement. Supratentorial figure  1C ). Among these 5, 3 had a deep Fazekas score of grade 2-3. Only 2 patients exhibited gadolinium-enhanced white matter including one patient with deep Fazekas score 1 exhibiting enhancement of a juxtacortical lesion and one patient with deep Fazekas score 3 with a single small enhancing area despite extensive deep white matter T2 hyperintensity ( figure 1D ).
Additional supratentorial changes included cortical laminar necrosis (1/39) and mesial temporal lobe T2 hyperintensity (4/39) with (3) and without (1) gadolinium enhancement ( figure 1D ). Three patients experienced an ischemic stroke, each of different etiology including large vessel, small vessel, and watershed mechanism. In the case of the watershed infarct, there was biopsy-proven cardiac involvement by ECD.
Enhancement-associated intramedullary spinal cord lesions occurred among 2/16 patients; one had multiple T2-hyperintense cervical lesions, and the other had a single T2-hypointense mass in the conus medullaris ( figure 2A ). T2-hypointense epidural infiltration penetrating the lateral foramina around nerve roots occurred in 2 patients with a single occurrence in the thoracic (1/16) and sacral (1/16) region (figure 2, B and C).
Orbital
Orbital involvement occurred among 13/42 patients including intraconal (8), extraconal (2), globe (3), and extraocular muscle (1) involvement (figure e-1, http://links. lww.com/CPJ/A8). Radiographic CNS involvement was not associated with an increase in mortality in the present study.
Hypothalamic pituitary axis
The patient who underwent dural biopsy demonstrated marked macrophage infiltrate of the dura with xanthomatous features and rare giant cells. BRAF V600E mutation analysis was not performed in this patient. Of the 3 patients with brain parenchymal biopsy, 1 demonstrated an inflammatory xanthogranulomatous pseudotumor (BRAF V600E mutation analysis not performed), 1 demonstrated a foamy macrophage infiltrate (BRAF V600E mutation positive), and 1 demonstrated KP1 positive foamy histiocytes and xanthomatous cells with myelin loss and decreased axonal density (BRAF V600E mutation negative). Langerin stains were negative.
BRAF mutation analysis was performed using whole blood PCR in 12 patients (8/12 BRAF V600E mutation positive), urine PCR in 3 patients (3/3 BRAF V600E mutation positive), immunohistochemistry in 9 patients (2/9 BRAF V600E mutation positive), Sanger sequencing in 1 patient (BRAF V600E mutation positive), and next-generation sequencing in 1 patient. Next-generation sequencing identified a BRAF V471F mutation, 2 NF1 splice sites (1641+1G>A, 7189+2T>G), along with MCL1 amplification mutation in 1 patient. No additional mutations were identified. BRAF V600E mutation status was not associated with increased risk of radiographic CNS involvement (p = 0.8).
Discussion
CNS involvement in ECD was common and consistent with prior case series. [5] [6] [7] [8] [9] Asymptomatic neurologic involvement was present in >10% of cases. Although asymptomatic lesions have been described previously, the present study estimates the relative frequency of asymptomatic lesions. 6, 10 Neuroimaging did not identify an HPA abnormality in half of patients with DI, despite MRI brain being performed for most patients with DI. This was seen in a prior study in which HPA lesions that might explain DI were "rarely found." 10 A variety of neuroimaging abnormalities were seen, similar to previously. [5] [6] [7] [8] [9] Obstructive hydrocephalus and spinal root compression, both due to dural involvement, are important to identify as they may be amenable to surgical intervention for symptomatic relief. Stellate-pattern extra-axial lesions and ependymal enhancement along the lateral ventricle with deep linear extension to the lentiform nucleus were not seen. 8 Radiographic CNS involvement was not associated with an increase in mortality in the present study. Previously, CNS involvement was shown to be an independent predictor of mortality using Cox proportional hazards regression analysis. 5 In a systematic review where the definition of neurologic involvement included the presence of DI, no association existed between neurologic involvement and survival. 9 ECD may overlap with Langerhans cell histiocytosis (LCH) (table 2), which is diagnosed by pathologic identification of Birbeck granules or CD1a+ immunohistochemistry, in ;20% of cases.
11 LCH is a multisystem disorder that frequently manifests with lytic bone lesions affecting the skull and HPA involvement including DI. 12 A study of 29 children with LCH demonstrated MRI signal abnormality in the brainstem and cerebellum (21%) primarily in the region of the dentate nucleus. 12 This suggests a similar distribution of neurologic involvement for LCH, although we excluded cases of pathologically confirmed LCH in the present study of ECD.
Treatment of ECD is not well-established. 2 A nonrandomized, observational cohort study suggested that Multinucleated histiocyte, CD68+, S100+, CD1a−; may be associated with immunoglobulin G4-related disease 11 Bone involvement Common (long-bone osteosclerosis) Common (osteolytic lesions including skull) 11, 12 Sporadic (osteolytic lesions) 11 Neuroradiologic involvement Brainstem/cerebellum T2 hyperintensity; cerebral white matter T2 hyperintensity; dural lesions Globus pallidus/dentate nucleus T1 hyperintensity; brainstem/cerebellum T2 hyperintensity; dural lesion from intracranial extension of skull lesion 12 Isolated dural lesion 18 Diabetes insipidus, % 30 17 12 
Rare 18
Other common sites of involvement
Perinephric fat, periaortic region, lungs, pericardium, orbits 1 Skin, bone marrow, lung, liver, spleen 11 Lymph nodes 11 Higher rates of radiographic involvement might have been found if specific imaging studies had been performed in all patients.
interferon-α improved survival. 5 BRAF inhibitors have been associated with dramatic improvement of CNS histiocytic infiltration in patients with BRAF V600E mutation. [13] [14] [15] BRAF is an oncogene involved in the RAS/RAF/MEK pathway. Among 3 patients with ECD with wild-type BRAF, the MEK inhibitor cobimetinib was associated with diminished lesion burden, including a single patient with dural lesions. 16 Cladribine has recently been reported to have moderate clinical efficacy and may be considered for patients without BRAF mutation. 17 Limitations of the present study include its retrospective nature. Imaging was performed as part of clinical care without a standardized procedure. Higher rates of radiographic involvement might have been found if specific imaging studies had been performed in all patients.
The present study demonstrates the range of CNS abnormalities present in patients with ECD. Some patients had lesions responsive to surgical intervention for symptomatic relief. DI was not always associated with neuroimaging abnormalities. We recommend MRI of the brain and spine along with screening laboratory investigations (serum electrolytes, serum osmolality, urine osmolality) for DI for all patients with ECD to clarify extent of neurologic involvement in addition to a bone scan or whole body PET-CT. Among individuals with symptoms suggestive of DI (including polydipsia or polyuria) or positive screening investigations, we recommend assessment by an endocrinologist for DI diagnosis and treatment.
